| Griesshammer, Martin |
| Recruiting | 3 | 1260 | Europe | Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios | West German Study Group, Eli Lilly and Company, Genomic Health®, Inc. | Breast Cancer Female | 08/26 | 03/28 | | |
| Active, not recruiting | 2 | 30 | Europe | Fedratinib Oral Capsule [Inrebic], Nivolumab | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Prof. F. Heidel, MH Hannover, Celgene International II S.á.r.l. | Primary Myelofibrosis, Secondary Myelofibrosis | 12/25 | 06/26 | | |
| Recruiting | N/A | 552 | Europe, US, RoW | | Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net | Myeloproliferative Neoplasm, COVID | 02/22 | 08/22 | | |
| Recruiting | N/A | 617 | Europe, RoW | | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline | Myelofibrosis | 12/25 | 12/28 | | |
NCT03125707: German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm) |
|
|
| Recruiting | N/A | 2172 | Europe | Registry study | University of Ulm | BCR-ABL1-Negative Myeloid Neoplasms | 09/45 | 09/45 | | |
| Wille, Kai |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
|
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 06/27 | 06/27 | | |
NCT06652438: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML |
|
|
| Not yet recruiting | 3 | 415 | Europe | Revumenib, Placebo | Stichting Hemato-Oncologie voor Volwassenen Nederland, German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network | Acute Myeloid Leukemia, Adult | 05/28 | 05/31 | | |
ARCHED, NCT05820841: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 330 | Europe | R-miniCHOP + Acalabrutinib, R-miniCHOP | Universität des Saarlandes, University of Leipzig, University Hospital Regensburg, Wuerzburg University Hospital, University Hospital of Gießen and Marburg, Saarland University Medical Center, AstraZeneca | Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma | 04/28 | 12/28 | | |
| Recruiting | N/A | 552 | Europe, US, RoW | | Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net | Myeloproliferative Neoplasm, COVID | 02/22 | 08/22 | | |
AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - the Biology and Outcome (BiO)-Project |
|
|
| Recruiting | N/A | 50000 | Europe | | University of Ulm | Acute Myeloid Leukemia (AML), MDS/AML | 12/44 | 12/44 | | |
